Finally Drugging The "Undruggable" Proteome
With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.
The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.
Join the pioneering directors, team leaders and senior scientists from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Hear case studies from Merck, Novartis, GSK, Pfizer, AstraZeneca, Biogen, PhoreMost, RAPT Therapeutics, Sprint Bioscience, Alkermes and more. Visit the website to see the full speaker line-up and case studies.
With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.
The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.
Join the pioneering directors, team leaders and senior scientists from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.
Hear case studies from Merck, Novartis, GSK, Pfizer, AstraZeneca, Biogen, PhoreMost, RAPT Therapeutics, Sprint Bioscience, Alkermes and more. Visit the website to see the full speaker line-up and case studies.
